Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | NR1H2 | P55055 | 4/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.37 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.35 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15248097 | 0.85 | USP2 (0.41) | USP2SMN1; SMN2NR1H2HDAC1ESR2 | |
| SCHEMBL20392811 | 0.83 | USP2 (0.39) | USP2SMN1; SMN2NR1H2HDAC1ESR2 | |
| SCHEMBL31080015 | 0.82 | USP2 (0.50) | USP2SMN1; SMN2NR1H2HDAC1ESR2 | |
| SCHEMBL1528547 | 0.81 | USP2 (0.38) | USP2SMN1; SMN2NR1H2HDAC1ESR2 | |
| SCHEMBL1528546 | 0.81 | USP2 (0.38) | USP2SMN1; SMN2NR1H2HDAC1ESR2 | |
| SCHEMBL827122 | 0.81 | USP2 (0.38) | USP2SMN1; SMN2NR1H2HDAC1ESR2 | |
| SCHEMBL21588714 | 0.80 | USP2 (0.44) | USP2SMN1; SMN2NR1H2HDAC1ESR2 | |
| SCHEMBL4768968 | 0.79 | MAPK10 (0.39) | USP2SMN1; SMN2NR1H2HDAC1ESR2 | |
| SCHEMBL17081081 | 0.77 | USP2 (0.42) | USP2SMN1; SMN2NR1H2HDAC1ESR2 | |
| SCHEMBL25845889 | 0.76 | NR1H2 (0.47) | USP2SMN1; SMN2NR1H2ESR2ADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1412078-B1 | PROCESSES FOR THE PRODUCTION OF AMINO-PROTECTED DERIVATIVES OF 4-AMINOMETHYLENE-PYRROLIDIN-3-ONE, GEMIFLOXACIN OR A SALT THEREOF | LG LIFE SCIENCES LTD (KR) | 2008-10-08 | — | — | EP | disclosed |
| US-7199242-B2 | Processes for the production of amino-protected derivatives of 4-aminomethylene-pyrrolidin-3-one and/or 4-aminomethylene-pyrrolidin-3-alkoxyimino derivatives and/or gemifloxacin or a salt thereof | LG LIFE SCIENCES LIMITED (KR) | 2007-04-03 | — | — | US | disclosed |
| US-7199242-B2 | Processes for the production of amino-protected derivatives of 4-aminomethylene-pyrrolidin-3-one and/or 4-aminomethylene-pyrrolidin-3-alkoxyimino derivatives and/or gemifloxacin or a salt thereof | LG LIFE SCIENCES LIMITED (KR) | 2007-04-03 | — | — | US | disclosed |
| US-7199242-B2 | Processes for the production of amino-protected derivatives of 4-aminomethylene-pyrrolidin-3-one and/or 4-aminomethylene-pyrrolidin-3-alkoxyimino derivatives and/or gemifloxacin or a salt thereof | LG LIFE SCIENCES LIMITED (KR) | 2007-04-03 | — | — | US | disclosed |
| EP-1068182-B1 | PROCESS FOR PREPARING A PROTECTED 4-AMINOMETHYL-PYRROLIDIN-3-ONE | LG LIFE SCIENCES LTD (KR) | 2005-06-08 | — | — | EP | disclosed |
| US-20050043546-A1 | Processes for the production of amino-protected derivatives of 4-aminomethylene-pyrrolidin-3-one and/or 4-aminomethylene-pyrrolidin-3-alkoxyimino derivatives and/or gemifloxacin or a salt thereof | LG CHEM, LTD. (KR) | 2005-02-24 | — | — | US | disclosed |
| EP-1412078-A1 | PROCESSES FOR THE PRODUCTION OF AMINO-PROTECTED DERIVATIVES OF 4-AMINOMETHYLENE-PYRROLIDIN-3-ONE AND/OR 4-AMINOMETHYLENE-PYRROLIDIN-3-ALKOXYIMINO DERIVATIVES AND/OR GEMIFLOXACIN OR A SALT THEREOF | SB Pharmco Puerto Rico Inc (US) | 2004-04-28 | — | — | EP | disclosed |
| WO-2003011450-A1 | PROCESSES FOR THE PRODUCTION OF AMINO-PROTECTED DERIVATIVES OF 4-AMINOMETHYLENE-PYRROLIDIN-3-ONE AND/OR 4-AMINOMETHYLENE-PYRROLIDIN-3-ALKOXYIMINO DERIVATIVES AND/OR GEMIFLOXACIN OR A SALT THEREOF | LG LIFE SCIENCES LIMITED (KR) | 2003-02-13 | — | — | WO | disclosed |
| US-6307059-B1 | PREPARATION OF QUINOLONE ANTIBIOTICS. | LG CHEMICAL, LTD (KR) | 2001-10-23 | — | — | US | disclosed |
| WO-2001040163-A1 | A PROCESS FOR PRODUCING AMINE COMPOUND WITH t-BUTOXYCARBONYL GROUP | KOREA FINE CHEMICAL CO.,LTD. (KR) | 2001-06-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050043546-A1 | Processes for the production of amino-protected derivatives of 4-aminomethylene-pyrrolidin-3-one and/or 4-aminomethylene-pyrrolidin-3-alkoxyimino derivatives and/or gemifloxacin or a salt thereof | CYP4X1, PM20D2, BRIX1 | USP2 3909/4885SMN1; SMN2 3131/4885NR1H2 4584/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.